All data are based on the daily closing price as of July 4, 2025
d

Daiichi Sankyo

4568.TSE
22.34 USD
-0.09
-0.40%

Overview

Last close
22.34 usd
Market cap
41.60B usd
52 week high
42.03 usd
52 week low
21.71 usd
Target price
40.44 usd

Valuation

P/E
20.7041
Forward P/E
20.8768
Price/Sales
3.1826
Price/Book Value
3.7013
Enterprise Value
37.27B usd
EV/Revenue
2.8571
EV/EBITDA
12.357

Key financials

Revenue TTM
13.06B usd
Gross Profit TTM
10.18B usd
EBITDA TTM
2.63B usd
Earnings per Share
1.08 usd
Dividend
0.42 usd
Total assets
23.18B usd
Net debt
-3.61B usd

About

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.
  • Symbol
    4568.TSE
  • Exchange
    TSE
  • Isin
    JP3475350009
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Mr. Sunao Manabe D.V.M., Ph.D.
  • Headquarter
    Tokyo
  • Web site
    https://www.daiichisankyo.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top